Video: Superheroes, Secret Identities & You| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Lupus Nephritis
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Search results for: inhibitor

Cardiovascular & Cancer Risk Factors with JAK Inhibitors

Arthritis Care & Research  |  October 9, 2024

In this study, researchers set out to determine the prevalence of baseline risk factors for cardiovascular outcomes and cancer among commercially insured patients with rheumatoid arthritis during their first dispensed treatment.

Filed under:ConditionsResearch ReviewsResearch RheumRheumatoid Arthritis Tagged with:JAK inhibitorsRA Resource CenterTNF inhibitors

When a JAK Inhibitor Fails

Michele B. Kaufman, PharmD, BCGP  |  January 24, 2024

What Are the Therapeutic Alternatives When a Janus Kinase Inhibitor Fails to Work? SAN DIEGO—Treatment alternatives after Janus kinase (JAK) inhibitor failure in real-life conditions were analyzed and presented at ACR Convergence 2023 by Pablo Francisco Muñoz Martínez, a rheumatologist at the Hospital Universitario y Politécnico La Fe, Sagunto, Spain.1 JAK inhibitors are newer, targeted…

Filed under:ACR ConvergenceBiologics/DMARDsDrug Updates Tagged with:ACR Convergence 2023JAK inhibitorsJanus Kinase Inhibitors

Pregnancy Outcomes in Patients Treated with TNF Inhibitors

Michele B. Kaufman, PharmD, BCGP  |  December 18, 2023

A study found the continuation of tumor necrosis factor inhibitor (TNFi) treatment in patients with chronic rheumatic inflammatory diseases after pregnancy diagnosis was not associated with worse outcomes than those who discontinued treatment with TNFi’s.

Filed under:ACR ConvergenceBiologics/DMARDsConditionsDrug UpdatesMeeting Reports Tagged with:ACR Convergence 2023pregnancypregnant womentumor necrosis factor inhibitor (TNFi)

Can SGLT2 Inhibitors Protect Our SLE Patients?

Samantha C. Shapiro, MD  |  December 4, 2023

SAN DIEGO—At ACR Convergence 2023, Plenary Session 2, April M. Jorge, MD, shared data concerning the potential cardio- and renal-protective benefits of sodium-glucose co-transporter-2 inhibitors in patients with systemic lupus erythematosus and lupus nephritis.

Filed under:ACR ConvergenceConditionsMeeting ReportsSystemic Lupus Erythematosus Tagged with:ACR Convergence 2023Lupus nephritis

A Dual Inhibitor Treatment for RA?

Michele B. Kaufman, PharmD, BCGP  |  July 17, 2023

TLL-018, a Janus kinase 1/tyrosine kinase 2 inhibitor, proved more effective for treating patients with RA than tofacitinib, according to a study by Zeng et al.

Filed under:Biologics/DMARDsDrug UpdatesMeeting Reports Tagged with:EULAR 2023

JAK Inhibitors vs. TNF Inhibitors: Understanding Infection Risks

Michele B. Kaufman, PharmD, BCGP  |  April 27, 2023

Research from Choi et al. provides insights into the risk of infection in patients with rheumatoid arthritis (RA), comparing patients treated with Janus kinase inhibitors vs. tumor necrosis inhibitors. The most frequent infection was herpes zoster, with patients treated with JAK inhibitors having a significantly greater risk of herpes zoster infection than those treated with TNF inhibitors.

Filed under:ACR ConvergenceDrug UpdatesMeeting Reports Tagged with:ACR Convergence 2022InfectionJAK inhibitorsJanus Kinase InhibitorsRheumatoid Arthritis (RA)TNF inhibitorstumor necrosis factor (TNF) inhibitors

TNF Inhibitors Associated with Neurological Adverse Events

Michele B. Kaufman, PharmD, BCGP  |  November 7, 2022

A study examined the association between TNF inhibitors and neurological demyelinating adverse events in patients with rheumatoid arthritis and spondyloarthritis using cohort data from five Nordic countries. Researchers showed that patients with SpA were more likely to experience adverse events than patients with RA.

Filed under:ConditionsDrug Updates Tagged with:adverse eventsbrainEULARneurological demyelinating adverse eventsTNF inhibitorstumor necrosis factor (TNF) inhibitors

JAK Inhibitors: Are All Promises Fulfilled?

Samantha C. Shapiro, MD  |  July 22, 2022

A decade after JAK inhibitors were approved, this EULAR 2022 session looks at whether the drugs have lived up to expectations.

Filed under:Drug UpdatesEULAR/OtherMeeting Reports Tagged with:EULARJAK inhibitorsjakinibsjanus kinase inhibitorRheumatoid Arthritis (RA)

Early Data on Novel MK2 Inhibitor to Treat Inflammatory Diseases Promising

Michele B. Kaufman, PharmD, BCGP  |  June 9, 2022

In a small preliminary study, the novel MK2 inhibitor, CC-99677, was safe and well tolerated by healthy participants. With daily dosing, the agent sustained reductions of tumor necrosis factor alpha and other cytokines for 14 days.

Filed under:ACR ConvergenceDrug UpdatesMeeting Reports Tagged with:ACR Convergence 2021CC-99677mitogen-activated protein kinase (MAPK)tumor necrosis factor

Risk of Adverse Outcomes Due to COVID-19 May Be Lower with TNF Inhibitor Monotherapy

Katie Robinson  |  May 5, 2022

Findings support the continued use of TNF inhibitor monotherapy in individuals with immune-mediated inflammatory diseases. In the study, these patients had a lower risk of hospitalization or death caused by COVID-19 than patients on other commonly prescribed treatment regimens

Filed under:Conditions Tagged with:COVID-19COVID-19 Global Rheumatology Allianceimmune-mediated inflammatory diseases (IMIDs)monotherapyTNF inhibitors

  • 1
  • 2
  • 3
  • …
  • 119
  • Next Page »
  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences